Vericel Co. (NASDAQ:VCEL) Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. reduced its stake in shares of Vericel Co. (NASDAQ:VCEL) by 17.7% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 6,448 shares of the biotechnology company’s stock after selling 1,389 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Vericel were worth $272,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. International Assets Investment Management LLC grew its stake in shares of Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 619 shares during the period. CWM LLC grew its position in shares of Vericel by 319.0% in the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 504 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 322 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in Vericel by 9.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 220 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Stephens raised their target price on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Truist Financial lifted their target price on shares of Vericel from $56.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Canaccord Genuity Group began coverage on shares of Vericel in a research report on Friday, August 9th. They set a “buy” rating and a $57.00 price target on the stock. Finally, Canaccord Genuity Group initiated coverage on shares of Vericel in a report on Friday, August 9th. They issued a “buy” rating and a $57.00 price objective for the company. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $57.71.

Vericel Price Performance

NASDAQ:VCEL opened at $55.89 on Wednesday. The company’s 50-day moving average is $44.37 and its two-hundred day moving average is $46.49. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of 946.33 and a beta of 1.66. Vericel Co. has a 1-year low of $32.31 and a 1-year high of $57.81.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The company had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. As a group, equities analysts anticipate that Vericel Co. will post 0.13 earnings per share for the current fiscal year.

Insider Activity at Vericel

In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total transaction of $235,361.55. Following the completion of the transaction, the director now owns 11,000 shares of the company’s stock, valued at $443,850. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven C. Gilman sold 5,833 shares of Vericel stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at $443,850. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,166 shares of company stock worth $1,200,764. Company insiders own 5.20% of the company’s stock.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.